A Rs 600 crore agreement signed by the Assam government on Sunday, November 1, 2026, is set to bring one of medicine's most precise cancer-fighting technologies to Gauhati Medical College and Hospital (GMCH) in Guwahati — promising Northeast India its first credible shot at world-class radiation oncology without the punishing journey to a metro city.

What a proton therapy facility at GMCH actually means

Proton beam therapy is not conventional radiation. Unlike standard X-ray-based radiotherapy, proton therapy delivers its lethal dose precisely at the tumour site and stops — sparing surrounding healthy tissue in a way that matters enormously for paediatric cancers, brain tumours, and cancers near the spine. It is the standard of care in advanced oncology centres globally, yet remains almost entirely absent from public hospitals across northeastern India.

Situating this facility at GMCH — Assam's oldest and largest government medical institution — gives it immediate credibility and catchment. The hospital already handles complex referral cases from across the seven sister states, meaning the proton unit would serve patients well beyond Assam's borders from the moment it opens.

Northeast's long journey to the nearest oncology centre — and why this changes it

For decades, cancer patients from Assam and neighbouring states have faced a grim arithmetic: travel thousands of kilometres to Kolkata, Mumbai, or Delhi for advanced treatment, burning through savings before a single session of therapy begins. The region's limited radiation oncology infrastructure has fed a cycle of late diagnoses, deferred treatment, and preventable deaths.

Several Indian states have already moved to close this gap through public-private partnerships that bring high-capital precision equipment into government hospital campuses. Assam's pact follows that model — pairing state commitment with private sector capability to build something that neither could finance alone. The broader national push, including the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) launched in 2010, laid policy groundwork for exactly this kind of state-level oncology investment.

The numbers that will determine whether 'affordable' holds

The Rs 600 crore project cost is substantial — proton therapy machines rank among the most expensive pieces of medical equipment on earth — but the government's stated aim of 'affordable cancer care' is the real test. The identity of the private partner, the agreed pricing structure for public patients, and the facility's integration with existing state and central cancer insurance schemes remain the crucial open questions.

What the government does with that partnership agreement — how it structures subsidised access for patients below the poverty line, how it links the facility to the Ayushman Bharat framework, and what timeline it sets for commissioning — will determine whether this becomes a model for the region or an elite unit that happens to sit inside a government campus.

Northeast India is watching. If Assam delivers proton therapy at a price that a family from rural Nagaland or Manipur can actually afford, the ripple effect on regional cancer care could be transformative. That is the promise on the table today.